The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Novartis
 
Shukui Qin
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Astellas Pharma; Bayer Yakuhin; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Gilead Sciences; Kaken Pharmaceutical; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Micron; MSD; Novartis; Ono Pharmaceutical; SERVIER; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Peter R. Galle
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Bayer; Blueprint Genetics; Bristol-Myers Squibb; Eisai; F. Hoffmann LaRoche; Ipsen; Lilly; Merck; MSD; Sirtex Medical
Research Funding - Bayer (Inst)
 
Michel Ducreux
Employment - Sandoz (I)
Honoraria - Amgen; Bayer; Celgene; Ipsen; Lilly; Merck Serono; MSD Oncology; Novartis; Roche/Genentech; Servier
Consulting or Advisory Role - Amgen; Celgene; HalioDx; Ipsen; Lilly; Merck Serono; Novartis; Pierre Fabre; Roche; Servier
Speakers' Bureau - Bayer; Celgene; Ipsen; Merck KGaA; Roche
Research Funding - Keocyt (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Ipsen; Merck Serono; Roche
 
Tae-You Kim
No Relationships to Disclose
 
Masatoshi Kudo
Honoraria - Bayer; Eisai; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ho Yeong Lim
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai
 
Valeriy Vladimirovich Breder
Honoraria - Bayer; BioCad; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - Bayer; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; Roche; Takeda
 
Philippe Merle
Honoraria - Onxeo
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; F. Hoffmann LaRoche; Ipsen; Lilly; MSD; Onxeo
Research Funding - Ipsen; Onxeo
Travel, Accommodations, Expenses - Abbvie; Bayer; F. Hoffmann LaRoche; Gilead Sciences; Ipsen; MSD
 
Ahmed Omar Kaseb
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - Bayer Health; Bristol-Myers Squibb; Exelixis; Merck
Consulting or Advisory Role - Bayer Health; Bristol-Myers Squibb; Exelixis; Merck
Research Funding - Adaptimmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Hengrui Pharmaceutical (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Bristol-Myers Squibb; Exelixis; Merck
 
Daneng Li
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Genentech; Ipsen; Lexicon; Taiho Pharmaceutical
Speakers' Bureau - Advanced Accelerator Applications; Eisai; Exelixis; Ipsen; Lexicon
Research Funding - Brooklyn ImmunoTherapeutics (Inst)
 
Yin-Hsun Feng
Research Funding - Kirin Pharmaceuticals
Travel, Accommodations, Expenses - Pfizer; Roche; Takeda
 
Wendy Verret
Employment - Roche/Genentech
 
Derek-Zhen Xu
Employment - F. Hoffmann LaRoche
 
Sairy Hernandez
Employment - Genentech
 
Beiying Ding
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Lilly; Merck; Roche/Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche; Lilly
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; IQVIA; MSD; Novartis; Ono Pharmaceutical